Tiragolumab and atezolizumab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with available therapies. It may be an option if your tumor has certain immune-related markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has spread or cannot be removed with surgery, and you've tried all standard treatments or can't take them.
- You are at least 18 years old.
- Your tumor has one of these features: high mutation burden (TMB ≥10), PD-L1 amplification, PD-L1 expression ≥5%, or certain immune cells (TILs) ≥5%.
- You are willing to have a tumor biopsy before and during treatment.
- Your overall health is good (able to do daily activities) and blood tests show your organs are working well.
- You have not had certain immunotherapies (like anti-PD-1 or anti-CTLA-4 drugs) or a prior severe immune reaction to immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
This Phase 2 trial tests the cancer medicines atezolizumab and tiragolumab in people with different solid tumors. It aims to see how well these drugs work and what side effects they cause in specific patient groups.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
This trial tests two immunotherapy drugs (atezolizumab and tiragolumab) for people with advanced triple-negative breast cancer that has not responded to standard treatments. It aims to see if this combination can shrink or slow the cancer.
This trial tests a single immunotherapy drug (tislelizumab) for people with advanced solid tumors that haven't responded to other treatments. It's for those who haven't had immunotherapy before and have a specific genetic marker in their tumor that suggests their immune system might be more active.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.